Fennec Pharmaceuticals (FENC) former director sells 10,000 shares under plan

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov sold 10,000 common shares on 2026-08-03 at $9.5800 per share in a sale classified as an open-market or private transaction. The sale was executed under a Rule 10b5-1 plan dated September 19, 2025, and left him holding 131,633 common shares directly.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Raykov Rosty

Role Insider

Sold 10,000 shs ($96K)

Type	Security	Shares	Price	Value
Sale	Common shares F1	10,000	$9.58	$96K

Holdings After Transaction: Common shares — 131,633 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025.

Key Figures

Common shares sold: 10000.0000 shares Sale price per share: $9.5800 Shares held after transaction: 131633.0000 shares +1 more

4 metrics

Common shares sold 10000.0000 shares Sale reported for 2026-08-03 by former director Rosty Raykov

Sale price per share $9.5800 Price per common share in the reported sale

Shares held after transaction 131633.0000 shares Direct common share holdings following the sale

Rule 10b5-1 plan date 2025-09-19 Date of trading plan governing the reported sale

Key Terms

Rule 10b5-1 plan, open market or private transaction, non-derivative

3 terms

Rule 10b5-1 plan regulatory

"Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market or private transaction financial

"Transaction code description: Sale in open market or private transaction"

non-derivative financial

"Transaction type is listed as non-derivative common shares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:07 PM Accepted by SEC EDGAR 08/04/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transaction did FENC report for Rosty Raykov?

Former director Rosty Raykov sold 10,000 common shares of FENNEC PHARMACEUTICALS INC. on 2026-08-03 at $9.5800 per share. The transaction is reported as a sale in an open-market or private transaction under a pre-established Rule 10b5-1 trading plan.

How many Fennec Pharmaceuticals (FENC) shares does Rosty Raykov hold after the sale?

After the reported transaction, Rosty Raykov holds 131,633 common shares of FENNEC PHARMACEUTICALS INC. directly. This figure reflects his position immediately following the 10,000-share sale disclosed in the Form 4 insider report filed for the August 3, 2026 transaction.

Was the August 3, 2026 FENC insider sale made under a Rule 10b5-1 plan?

Yes. The 10,000 FENC shares sold by Rosty Raykov were executed under a Rule 10b5-1 plan dated September 19, 2025. Both the form-level checkbox and a transaction footnote confirm that the sale followed this pre-arranged trading plan.

What type of security did the FENC insider sell in this Form 4?

The insider transaction involved common shares of FENNEC PHARMACEUTICALS INC., classified as a non-derivative security. The report lists one sale transaction of common shares, with no related derivative exercises or option transactions disclosed alongside this sale.

Is Rosty Raykov currently a director of Fennec Pharmaceuticals (FENC)?

The insider report identifies Rosty Raykov as a "Former Director" of FENNEC PHARMACEUTICALS INC. While he remains a reporting person for this transaction, the designation indicates he no longer serves on the company’s board in an active director role.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raykov Rosty

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former Director

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	08/03/2026		S		10,000	D	$9.58	131,633	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a 10b5-1 plan dated September 19, 2025.

	/s/ Rosty Raykov	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)